Despite being frequently diagnosed, there has been very limited study of efficacious treatments for schizoaffective disorder. Paliperidone had been approved for the treatment of schizoaffective disorder, and a recently completed relapse prevention study of the use of a once-monthly injectable paliperidone formulation has also led to an indication for that preparation to treat schizoaffective disorder.
INTRODUCTION

Schizoaffective Disorder
Schizoaffective disorder has been a controversial diagnosis. It has long been recognized that many patients with psychotic symptoms do not neatly fit into the Kraepelinian diagnostic dichotomy of what we now label schizophrenia and bipolar disorder, but rather present with varying presentations of mood and psychotic symptoms. In 1933, Kasinin proposed the term ''schizoaffective psychosis'' to designate individuals prominently displaying both psychotic and mood symptoms, claiming that those so diagnosed would have a better prognosis [1] . The ''affective'' portion of the term ''schizoaffective'' itself remains something of an anachronistic misnomer, as aside from the psychotic symptomatology, there is also a primary disturbance in mood (a pervasive and sustained emotional state), not affect per se.
Affect is defined as observable behaviors that express a current emotional state, which may fluctuate; in the past, other mood disorders were also inaccurately labeled ''affective'' disorders.
Early versions of the Diagnostic and
Statistical Manual of Mental Disorders (DSM) included this entity using slightly different terminology, such as ''schizophrenic reaction, schizoaffective type'' in DSM-I and ''schizophrenia, schizoaffective type'' (either excited or depressed) in DSM-II, but in 1980 in DSM-III it was named ''schizoaffective disorder, '' and was the only diagnosis in that edition that did not employ specific diagnostic criteria. In DSM-III-R (1987) criteria were introduced, which required a period of psychosis meeting criteria for schizophrenia during which mood symptoms were present for ''more than a brief'' period of time, and also a period of psychotic symptoms without mood symptoms of at least two weeks, to distinguish schizoaffective disorder from a mood disorder with psychotic symptoms. DSM-IV (1994) further recognized two subtypes of schizoaffective disorder: ''depressive type'' and ''bipolar type,'' and DSM-IV-TR (2000) required that the mood symptoms must be present for ''a substantial portion'' of the course of the disorder, without further quantification.
This vagueness in the diagnostic criteria has been further compounded by the common difficulty in obtaining an accurate longitudinal description of the course of patients' symptoms. It is commonly not possible to adequately establish accurate periods of time for which prominent mood symptoms have been present over the course of a patient's history with and without delusions and hallucinations, and verify that such symptoms were not caused by the use of, or withdrawal from, substances of abuse, let alone formally decide on the definition of ''substantial period.'' Not surprisingly, therefore, kappa values for diagnostic agreement have been notably poor:
Hiller et al. [2] reported a kappa of 0.08 using DSM-III-R criteria for schizoaffective disorder, and Maj et al. [3] reported a kappa of 0.22 using DSM-IV criteria, far below the more desirable range indicating at least moderate interrater agreement (0.4-0.6).
Appreciably better kappa values have been reported using International Classification of Diseases (ICD)-10 criteria, although that criteria set is quite similar to that of DSM-IV-TR.
However, a study in Denmark of patients with hospital discharge diagnoses of schizoaffective disorder found that none met DSM-IV-TR criteria and only 10% met ICD-10 criteria [4] . Seeking to improve reliability, DSM-5 (2013) usefully added the specification that the symptoms of a major mood episode were present for the majority of the total duration of the active and residual portions of the illness, which is somewhat more specific, although whether this will appreciably improve diagnostic reliability and validity must await future study [5] . Exploring issues regarding the validity of the diagnosis, a detailed review by Kantrowitz and Citrome [6] examined possible differentiating characteristics that would distinguish schizoaffective disorder from schizophrenia and bipolar disorder, including prognosis, genetic linkage studies, neuropsychological testing and pharmacological response, finding at best very modest evidence, although some results of neurophysiological sensory testing pointed towards some possible discriminating characteristics. Likewise, a longitudinal study of first-admission patients with a diagnosis of schizoaffective disorder did not generate support for the validity of the diagnosis of schizoaffective disorder based on symptom course and outcomes [7] .
In fairness, however, it should be noted that schizophrenia and bipolar disorder themselves do not admit of neatly separating genetic findings, with not only numerous proposed genetic linkages, but with some that appear to be common for both schizophrenia and psychotic bipolar disorder [8] . Moreover, there have been thoughtful proposals to formulate schizophrenia, schizoaffective disorder and bipolar disorder as representing more of a continuous spectrum, or viewed in a dimensional approach [9] . Clearly, this is still an enduring area of controversy; it remains a significant nosologic challenge for the field's attempts to skillfully ''carve Nature at its joints''.
Given these concerns, one must explain why we have the diagnostic category of schizoaffective disorder. Of most relevance is the fact that this diagnosis is very commonly used, with an estimated lifetime prevalence of 0.3% [10] , that is, a third or more as common as the diagnosis of schizophrenia, and translating to about 750,000 adult Americans. It likely serves as a useful clinical marker for the clinician to consider the adjunctive use of mood stabilizers or antidepressants in a given patient, which indeed is commonly done, although there is little high-quality evidence available supporting the efficacy of these adjunctive treatments. Notably, in 2009, the Food and Drug Administration (FDA) approved paliperidone for the treatment of schizoaffective disorder, the first time that the agency recognized this as a valid diagnostic entity for a therapeutic indication [11] . Since that time, when new antipsychotic agents have been submitted for approval using studies that enroll both individuals with schizophrenia and schizoaffective disorder, the FDA has examined data for those two diagnostic groups separately. Recently, the FDA expanded the indication for paliperidone, to include relapse prevention of schizoaffective disorder using a long-acting injectable (LAI) formulation of paliperidone, paliperidone palmitate [12] .
Paliperidone
Paliperidone (trade name Invega Ò ; Janssen), the 9-hydroxy active metabolite of risperidone (trade name Risperdal Ò ; Janssen) responsible for most of the antipsychotic potency of risperidone, is an antipsychotic medication that was developed by Janssen Pharmaceuticals, and was approved by the FDA in 2006 for the indication of the treatment of schizophrenia [11] . It is available in an oral extended-release formulation (paliperidone ER) that employs two drug layers and an osmotically active core layer that pushes the drug out (''OROS,'' a patented technology), allowing for slow, more even drug release supporting convenient once-daily dosing. Like other second-generation antipsychotics, it is believed that paliperidone's antipsychotic mechanism of action is antagonism at dopamine D2 receptors and serotonin-2A receptors in the brain, the latter action also helping limit some extrapyramidal adverse effects. Paliperidone is also an antagonist at a 1 and a 2 adrenergic and H 1 histamine receptors, but, unlike most first-generation antipsychotics, not at muscarinic cholinergic receptors [13] . Paliperidone does not substantially inhibit the CYP450 hepatic enzymes, and is a weak inhibitor of P-glycoprotein but only at high concentrations; it is therefore also not likely to significantly affect the metabolism of other drugs. Additionally, one brief case report was identified regarding the combined use of paliperidone palmitate and olanzapine pamoate in treatment-resistant schizoaffective disorder [16] . Another abstract briefly addressed the subsequently published full report of the relapse prevention trial. For added context, we also reviewed some key studies of paliperidone ER in the treatment of schizoaffective disorder.
METHODS
EFFICACY OF PALIPERIDONE FOR SCHIZOAFFECTIVE DISORDER
Acute Studies
There have been two acute clinical trials of the oral formulation paliperidone ER for schizoaffective disorder [17, 18] . A pooled analysis of these two 6-week registration trials of paliperidone ER for the acute treatment of individuals aged 18-65 years with schizoaffective disorder diagnosed using the Structured Clinical Interview for DSM-IV Disorders (SCID) included 614 subjects in the intent-to-treat population; 414 were randomized to receive paliperidone ER 3-12 mg/day and 200 to receive placebo [19] . Of these, 275 (45%) of subjects had been receiving adjunctive treatment with mood stabilizers and/or antidepressants; these adjunctive medications were continued for both treatment groups. All enrolled subjects were experiencing an acute exacerbation of their psychotic disorder at screening; had a Positive and Negative Syndrome Scale (PANSS) score C60 with a score C4 on two or more of the PANSS items hostility, excitement, tension, uncooperativeness and poor impulsive control; had significant mood symptoms as evidenced by a score C16 on the Young Mania Rating Scale (YMRS) and/or a score C16 on the Hamilton
Rating
Scale for Depression, 21-item (HAM-D-21).
In one study (ClinicalTrials.gov identifier, NCT00397033), subjects receiving paliperidone were randomized to receive 9-12 mg of paliperidone/day or 3-6 mg of paliperidone/day (dosed at the higher number, and later reduced if clinically indicated) [17] . In the other study (ClinicalTrials.gov identifier, NCT00412373), those randomized to paliperidone received 6 mg/day to start, but were then flexibly dosed, as clinically appropriate, in the range of 3-12 mg/day [18] . Both studies stratified randomization by study center and by whether the subject was being concurrently treated with mood stabilizers and/or antidepressants. The primary efficacy outcome measure for both studies was the change in the PANSS total score from baseline to endpoint, and secondary efficacy measures included changes in the Clinical Global Impressions of Severity for Schizoaffective Disorder (CGI-S-SCA), PANSS factor scores, YMRS, and HAM-D-21 scores [20] .
Demographic and clinical characteristics at baseline were similar for the treatment groups. Overall, 275 subjects were taking mood stabilizers and/or antidepressants; 69% of this group were taking mood stabilizers (principally valproate) and 59% were taking antidepressants.
Subjects randomized to paliperidone ER improved significantly more from day 4 to study endpoint, the placebo-adjusted least square mean (SE) difference at last observation carried forward (LOCF) for the PANSS total score was -7.8 (1.7), with P\0.001, and an effect size of 0.41; both subgroups with and without adjunctive mood stabilizer/antidepressant adjunctive treatment improved significantly more with paliperidone compared with placebo treatment. Secondary measures all were significantly better for the paliperidone treatment group as well, compared with placebo.
Maintenance (Prevention of Relapse)
A randomized, double-blind, placebo-controlled study with a 15-month relapse prevention phase examined the efficacy of monthly intramuscular injections of paliperidone palmitate compared with placebo during that phase (ClinicalTrials.gov identifier, NCT011193153) [21] . As in the acute studies of paliperidone, enrollees were diagnosed with schizoaffective disorder using the SCID interview (DSM-IV, Clinician Version), and were stratified by study center and by subjects' concurrent use of mood stabilizers or antidepressants or the lack of such treatment, and by study center in this international study. Those who had received treatment with both mood stabilizers and antidepressants were excluded from study participation (this was not a criterion in the previous acute study), as were individuals who had begun treatment with mood stabilizers or antidepressants or had dosage changes in the 30 days prior to screening. Pre-study treatment with benzodiazepines was also allowed to [22] .
There were 667 subjects who enrolled and received at least one dose of medication in the open-label phase; 334 were randomized 1:1 in the double-blind phase to paliperidone palmitate or placebo injections. In the double-blind period, the most commonly used dose of paliperidone palmitate was 156 mg (47.0%), followed by 234 mg (38.4%), 117 mg (9.8%), and 78 mg (4.9%). 15.2% of those randomized to paliperidone palmitate relapsed, as compared with 33.5% of those receiving placebo (hazard ratio 2.49 times greater for placebo, 95% confidence interval 1.55-3.99, P\0.001; number needed to treat 6). For those receiving adjunctive mood stabilizers or antidepressants, the relapse risk was 2.03 times for those on placebo compared with paliperidone; for those not receiving adjunctive mood stabilizers or antidepressants, the relapse risk was 3.38 times for those on placebo compared with paliperidone. Overall, paliperidone palmitate was superior to placebo in maintaining functioning measured by the PSP scale (P = 0.014, mixed-model repeated measures).
Significant improvements were also found at study endpoint for HAM-D-21, YMRS, PANSS, and CGI-S-SCA total scores for the paliperidone group, compared with the placebo group. Of the second-generation antipsychotics, risperidone appears somewhat more likely to cause extrapyramidal side effects, and its pharmacokinetic properties are not conducive to monthly maintenance injections for most; it also requires a period of initial oral supplementation. Olanzapine pamoate has been associated with severe sedation as a rare but serious adverse reaction (post-injection delirium sedation syndrome), and patients must be observed for at least three hours after injections in a registered facility with ready access to emergency services [23] . One US multisite, double-blind randomized head-to-head comparison of haloperidol decanoate to paliperidone palmitate in the maintenance treatment of patients diagnosed with schizophrenia or schizoaffective disorder found no significant difference in the rate of efficacy failure, and on the safety side reported more weight gain and increased prolactin levels in those on paliperidone palmitate, and more akathisia in patients taking haloperidol decanoate [24] . Aripiprazole, a D2 partial agonist, is also available as a long-acting injection, and an application of a formulation from a different manufacturer is currently under FDA review [25] .
TOLERABILITY OF PALIPERIDONE FOR SCHIZOAFFECTIVE DISORDER
The issue of acquisition cost is a significant one, as access to the much more expensive, branded drugs is being affected by their needing to be reviewed for prior authorization by most pharmacy benefit managers. 
SUMMARY AND CONCLUSIONS: BALANCING EFFICACY AND SAFETY
Paliperidone appears to be an effective modality not only in the acute treatment of schizoaffective disorder, but in preventing relapse for those with this disorder, the latter as evidenced in a 15-month maintenance of effect trial of paliperidone palmitate as both a monotherapy and as adjunct to oral mood stabilizers or antidepressant medication. Paliperidone is generally tolerated well, although its propensity to increase prolactin levels and cause extrapyramidal side effects and weight gain should be recognized. It can be used with adjunctive mood stabilizers or antidepressants, if they appear indicated. Favorable characteristics include its not requiring an initial oral supplementation period because of favorable pharmacokinetic parameters, and not being significantly affected by drug-drug interactions or CYP450 hepatic enzyme poor-or rapid-metabolizer status, decided advantages for some patients, although dosage adjustments may be needed for those with poor renal function. If the three-month version is also effective for those with schizoaffective disorder, this will prove a considerable benefit in treating non-adherent individuals or those who elect to receive a medication 4 times a year for convenience.
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